Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter …
E Abraham, PF Laterre, J Garbino… - Critical care …, 2001 - journals.lww.com
Objective Phase III study to confirm a trend observed in a previous phase II study showing
that a single dose of lenercept, human recombinant p55 tumor necrosis factor receptor-
immunoglobulin G1 (TNFR55-IgG1) fusion protein, decreased mortality in patients with
severe sepsis or early septic shock. Design
that a single dose of lenercept, human recombinant p55 tumor necrosis factor receptor-
immunoglobulin G1 (TNFR55-IgG1) fusion protein, decreased mortality in patients with
severe sepsis or early septic shock. Design